AU764260B2 - Method of producing cyclene - Google Patents
Method of producing cyclene Download PDFInfo
- Publication number
- AU764260B2 AU764260B2 AU16543/00A AU1654300A AU764260B2 AU 764260 B2 AU764260 B2 AU 764260B2 AU 16543/00 A AU16543/00 A AU 16543/00A AU 1654300 A AU1654300 A AU 1654300A AU 764260 B2 AU764260 B2 AU 764260B2
- Authority
- AU
- Australia
- Prior art keywords
- cyclene
- hours
- process according
- solvent
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
Abstract
The invention relates to a novel one-pot method of producing cyclene.
Description
WO 00/32581 PCT/EP99/09089 Process for the Production of Cyclene The invention relates to the subject that is characterized in the claims, a new process for the production of cyclene.
Cyclene (1,4,7,10-tetraazacyclododecane) is a frequently.
used starting material in the production of macrocyclic complexing agents and is mainly used in the area of nuclear resonance tomography as a ligand forgadolinium. Two preparations are already commercially available with ProHance(R) of Bristol-Myers-Squibb and Dotarem(R) of Guerbet. Special research and development projects also use cyclene as a starting material. There is therefore a need for an easy and economical process for the production of this educt.
One of the first published processes (Richman and Atkins, J.
Am. Chem. Soc. 1974, 96, p. 2268) employs the cyclization of a sodium bis-sulfonamide with a corresponding functionalized diethylene sulfonamide. In their synthesis, Weisman and Reed (J.
Org. Chem. 1996, 61, pp. 5186-5187) use the reaction of a bisthioimidoester with triethylenetetramine for the creation of a tricyclic bis-imine, which is ultimately hydrolyzed to cyclene after reduction.
The processes of V. Panetta et al. (Tetrahedron Lett. 1992, Vol. 33, No. 38, pp. 5505-5508), which perform a cyclization of a tetra-trifluoromethanesulfonic acid amide of triethylenetetramine with 1,2-dibromoethane, follow a more indirect approach to cyclene. The last reaction step comprises the release of cyclene. The process of the Nycomed Company (WO 96/28433) after the production of tribenzylcyclene is also dependent on such a procedure. The synthesis is accomplished by the reaction of a suitable triamine with a monoamine or the two suitable diamines.
The process that is disclosed in DE 19608307 and that contains a tetramerization of N-benzylaziridine as a key step also results in tetrabenzylcyclene.
As described in WO 97/31005 and US 5,587,451, the Dow Chemical Company uses a bis-imidazoline that starts from triethylenetetramine as an intermediate product. The rings in the tetracyclic intermediate product are closed with 1,2dibromoethane. The subsequent hydrolysis releases the cyclene.
As described in WO 97/49691, the Bracco Company uses a direct approach to cyclene, which starts with the condensation of triethylenetetramine with glyoxal which was already disclosed by Weisman et al. (Tetrahedron Lett. 1980, Vol. 21, pp. 335-338).
Then, the latter is converted.into a tetracyclic intermediate compound by reaction with 1,2-dibromoethane. The removal of the ethylene bridge that connects the four heteroatoms is carried out by oxidation with bromine with subsequent hydrolysis (or else by hydrolysis with a primary diamine, WO 98/49151). The total yield is indicated with H, /ff\ H [N NI NH 2
NH
2 1) Ca(OH) 2
/H
2 0 2) Glyoxa! 50C 3h 75%
NIND
I I H H BrCH 2
CH
2 Br Na 2
CO
3
DMAC
8000 6h
CNN
Li Br 2
H
2 0 pH 4.5 2500 18h Diagram 1: 97/4 96 91) N
N
Li 4 NaCH H 2 0 pH 14 18500 15 bar 5h 68% H H N ND H LiN Synthesis Sequence of the Bracco Company (WO The synthesis that is disclosed in WO 96/28432 of the Nycomed Company resembles the above-described synthesis, with the decisive difference being the hydrolysis of the central ethylene bridge. Here, the reaction is achieved by addition of hydroxylamine in an ethanolic solution while being heated. The total yield for this reaction sequence is approximately H, ff'\ /,H KNH NH 2 Glyoxal I_ EtOHN N 2000 20h 75% <N N N N H H BrCH 2
CH
2 BrI
DMF
20*C 20h 70% F> Li:
NH
2 0H* HCI H /f7 H EtOH N N 18h N N H" H Diagram 2: Synthesis Sequence of the Nycomed Company (WO 96/28432) Evaluation of the Process: The process according to WO 97/49691, supported by experimental reworking, has some decisive drawbacks, which are summarized briefly below: The production of the tricyclic compound cannot be reproduced as described, since: The calcium hydroxide cannot be quantitatively separated.
Larger amounts of water must be distilled off.
The product does not accumulate as an oil, as indicated.
The purification of the tetracyclic compound is very expensive: The extraction of the product from a solid reduces the yield.
Hydrolysis into cyclene has proven to be very difficult: An autoclave reaction must be performed at pH 14 and at 185 0
C.
The product crystallizes poorly and with heavy contamination from the reaction solution.
The process according to WO 96/28432 also gives rise to criticism. The basic drawbacks are listed below: All synthesis stages have long stirring times.
The purification of the tetracyclic compound is carried out via a preparative column chromatography.
The hydrolysis to cyclene lasts for a very long time, and the indicated purification method does not yield the product in the desired purity.
All other processes comprise multistage synthesis sequences, in which intermediate products are isolated, which generally is time-consuming and raw material-intensive. The process of Weismann and Reed is ruled out for commercial synthesis, since it is dependent on dithiooxamide (about DM 400/100 g) as one of the starting materials. In the process of Richman and Atkins as well as V. Panetta et al., correspondingly protected amines must first be prepared. After the reaction has been completed, as also in the process of the Dow Chemical Company, Nycomed (WO 96/28433) and Schering (DE19608307), the cleavage of these protective groups is necessary as an additional reaction step, which produces a poorer material balance relative to the desired product. In the case of tetramerization of benzylaziridine, it is necessary to work with large amounts of carcinogenic substances.
A profitable process should use raw materials that are as reasonably priced, as environmentally safe and as easily accessible as possible. The reaction times should also be short and should occur with little energy use. Moreover, the amounts of material during the overall synthesis should be as small as possible.
This object is achieved by this invention.
It has been found that a process for the production of cyclene H H N N .N N H H characterized in that in.a single-pot process, triethylenetetramine is reacted with 40% glyoxal at 20 0 C to 80 0
C
in a polar, protic solvent, preferably methanol, ethanol, isopropanol, butanol, glycol, water or mixtures thereof, especially preferably ethanol, within 4 to 40 hours, preferably to 20 hours; after the solvent has been removed, the intermediate tricyclic compound that is thus formed is alkylated to the two secondary amine-nitrogens with a 1,2-difuntionalized alkylating agent X(CH 2 2 X, in which X stands for a nucleofuge group, preferably with 1,2-dibromoethane, 1,2-dichloroethane, 1,2-ditosylethane, 1,2-dimesylethane or 1,2-diiodoethane, especially preferably with 1,2-dichloroethane in a polar aprotic solvent, preferably in N,N-dimethylformamide (DMF), N,Ndimethylacetamide (DMAC), N-methylpyrrolidone (NMP), tetramethyl urea, formamide or dimethylpropylene urea (DMPU), especially preferably in DMF, optionally in the presence of an auxiliary base, preferably sodium carbonate, potassium carbonate, calcium carbonate, sodium bicarbonate, potassium hydrogen carbonate, magnesium carbonate, magnesium hydrogen carbonate, lithium hydroxide or lithium carbonate, especially preferably without an auxiliary base, at 20 to 120 0 C, preferably 30 to 70 0 C, within 2 to 24 hours, preferably 6 to 10 hours; after the solvent has been removed, the thus obtained condensation product is treated with hydrazine hydrate in a polar protic solvent, preferably methanol, ethanol, isopropanol, butanol, glycol, water and/or mixtures thereof, especially preferably ethanol, at a pH of 3 to 6, preferably 3 to 4, 12 to 48 hours, preferably 25 to 35 hours, at reflux temperature; then the cyclene is released from the cyclene salt by adding a base, preferably sodium hydroxide, potassium hydroxide, calcium hydroxide or a basic ion exchanger, especially preferably sodium hydroxide and potassium hydroxide, and after the reaction solution is evaporated to the dry state, it is isolated, surprisingly enough achieves the above-mentioned object.
The isolation of the cyclene is preferably carried out by crystallization from toluene, trifluoromethylbenzene or diethoxymethane, whereby the latter is especially preferred.
By way of example, diagram 3 again sheds light on the process of the synthesis according to the invention: H\
H
N N
NH
2
NH
2
TETA
1) Glyoxal /EtOH 2) CICH 2
CH
2 CI /DMF 40°C 8h 3) H 2
N-NH
2
H
2 0 pH 4 /HCI Reflux 30h 4) KOH pH 13
DEM
65% von TETA H H N-- <N N H H- H [Key:] von of Advantages of the Process: The process for the production of cyclene according to the invention has considerable advantages relative to the previous processes due to its design as a-single-pot process.
No time-intensive and raw material-intensive isolating steps of the intermediate products are necessary.
The reaction with amine is carried out without generating considerable amounts of by-products.
The raw materials are reasonably priced and easily accessible.
Few wastes accumulate.
The total synthesis time is short.
A new, economical purification process for cyclene is used.
The yield is higher than in the process of the prior art.
The following example is used for a more detailed explanation of the subject of the invention.
Example 1 1,4,7,10 Tetraazacyclododecane cyclene): g of triethylenetetramine (0.342 mol) is dissolved in 1 1 of ethanol and mixed with 39 ml. of 40% glyoxal in water (0.342 mol) at room temperature. After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil, which is taken up in 400 ml of dimethylformamide and mixed with 81.2 ml (101.5 g 1.026 mol) of 1,2-dichloroethane, is obtained.
After 8 hours of stirring at 40 0 C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to about,pH 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g 3.42 mol) of hydrazine hydrate is added to this reaction solution at room temperature, and it is heated under reflux for 30 hours. The reaction solution is set at pH 13 with solid potassium hydroxide. The reaction solution is subsequently concentrated by evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the solvent is removed. The residue is mixed with 25 g of activated carbon and 100 ml of formaldehyde diethylacetal, and it is heated under reflux for some time before the hot solution is filtered through a membrane. After the solution is cooled, the product is isolated by filtration. 38.3 g of cyclene (0.222 mol 65% of theory) is obtained as a crystalline solid.
Example 2 1,4,7,10-Tetraazacyclododecane cyclene) g of triethylenetetramine (0.342 mol) is dissolved in 1 1 of ethanol and mixed at room temperature with 39 ml of glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which then is taken up in 400 ml of dimethylformamide and mixed with 88.5 ml (192.8 g 1.026 mol) of 1,2-dibromoethane. After 6 hours of stirring at 40 0 C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to pH 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g 3.42 mol) of hydrazine hydrate is added to this reaction solution at room temperature, and it is heated under reflux for 30 hours. The reaction solution is set at pH 13 with solid potassium hydroxide. The reaction solution is subsequently concentrated by.evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the solvent is removed again in a vacuum. The residue is mixed with g of activated carbon and 150 ml of formaldehyde diethylacetal, and it is heated under reflux for some time before the hot solution is filtered through a membrane. After the solution is cooled, the product is isolated by filtration.
39.5 g of cyclene (67% of theory) is obtained as a crystalline solid.
Example 3 1,4,7,10-Tetraazacyclododecane cyclene) g of triethylenetetramine (0.342 mol) is dissolved in 1 1 of ethanol and mixed at room temperature with 39 ml of glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which is then taken up in 400 ml of dimethylformamide and is mixed with 82.6 ml (274.8 g 1.026 mol) of 1,2-diiodoethane. After 5 hours of stirring at 40 0 C, it is concentrated by evaporation in a vacuum, the-residue is taken up in 400 ml of ethanol and acidified to pH 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g 3.42 mol) of hydrazine hydrate is added to this reaction solution at room temperature, and it is heated under reflux for 30 hours. The reaction solution is set at pH 13 with solid potassium hydroxide. The reaction solution is subsequently concentrated by evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the solvent is removed again in a vacuum. The residue is mixed with g of activated carbon and 150 ml of formaldehyde diethylacetal, and it is heated under reflux for some time before the hot solution is filtered through a membrane. After the solution is cooled, the product is isolated by filtration.
37.1 g of cyclene (63% of theory) is obtained as a crystalline solid.
Example 4 1,4,7,10-Tetraazacyclododecane cyclene) g of triethylenetetramine (0.342 mol) is dissolved in 1 ml of methanol and mixed at room temperature with 39 ml of glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which then is taken up in 400 ml of dimethylformamide and mixed with 81.2 ml (101.5 g 1.026 mol) of 1,2-dichloroethane. After 8 hours of stirring at 40 0 C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to pH 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g 3.42 mol) of hydrazine hydrate is added to this reaction solution at room temperature, and it is heated under reflux for 30 hours. The reaction solution is set at pH 13 with solid potassium hydroxide. The reaction solution is subsequently concentrated by evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the solvent is removed again in a vacuum. The residue is mixed with g of activated carbon and 150 ml of formaldehyde diethylacetal, and it is heated under reflux for some time before the hot solution is filtered through a membrane. After the solution is cooled, the product is isolated by filtration.
37.7 g of cyclene (64% of theory) is obtained as a crystalline solid.
Example 1,4,7,10-Tetraazacyclododecane cyclene) g of triethylenetetramine (0.342 mol) is dissolved in 1 1 of ethanol and mixed at room temperature with 39 ml of glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which then is taken up in 400 ml of dimethyl acetamide and is mixed with 81.2 ml (101.5 g 1.026 mol) of 1,2dichloroethane. After 8 hours of stirring at 40 0 C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to pH 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g 3.42 mol) of hydrazine hydrate is added to this reaction solution at room temperature and heated under reflux for 30 hours. The reaction solution is set at pH 13 with solid potassium hydroxide. The reaction solution is subsequently concentrated by evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the solvent is removed again in a vacuum. The residue is mixed with 25 g of activated carbon and 150 ml of formaldehyde diethylacetal and heated under reflux for some time before the hot solution is filtered through a membrane. After the solution is cooled, the product is isolated by filtration. 37.7 g of cyclene (64% of theory) is obtained as a crystalline solid.
Example 6 1,4,7,10-Tetraazacyclododecane cyclene) g of triethylenetetramine (0.342 mol) is dissolved in 1 1 of ethanol and mixed at room temperature with 39 ml of glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which then is taken up in 400 ml of tetramethylurea and mixed with 81.2 ml (101.5 g 1.026 mol) of 1,2dichloroethane. After 8 hours of stirring at 40 0 C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to pH 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g 3.42 mol) of hydrazine hydrate is added to this reaction solution at room temperature and heated under reflux for 30 hours. The reaction solution is set at pH 13 with solid potassium hydroxide. The reaction solution is subsequently concentrated by evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the solvent is again removed in a vacuum. The residue is mixed with 25 g of activated carbon and 150 ml of formaldehyde diethylacetal, and it is heated under reflux for some time before the hot solution is filtered through a membrane. After the solution is cooled, the product is isolated by filtration. 37.1 g of cyclene (63% of theory) is obtained as a crystalline solid.
Example 7 1,4,7,10-Tetraazacyclododecane cyclene) g of triethylenetetramine"(0.342 mol) is dissolved in 1 1 of ethanol and mixed at room temperature with 39 ml of glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which then'is taken up in 400 ml of tetramethylurea and mixed with 88.5 ml (192.8 g 1.026 mol) of 1,2dibromoethane. After 6 hours of stirring at 40 0 C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to pH 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g 3.42 mol) of hydrazine hydrate is added to this reaction solution at room temperature and heated under reflux for 30 hours. The reaction solution is set at pH 13 with solid potassium hydroxide. The reaction solution is subsequently concentrated by evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the solvent is removed again in a vacuum. The residue is mixed with 25 g of activated carbon and 150 ml of formaldehyde diethylacetal and heated under reflux for some time before the hot solution is filtered through a membrane. After the solution is cooled, the product is isolated by filtration. 37.6 g of cyclene (64% measured) is obtained as a crystalline solid.
Example 8 1,4,7,10-Tetraazacyclododecane cyclene) g of triethylenetetramine (0.342 mol) is dissolved in 1 1 of methanol and mixed at room temperature with 39 ml of glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which then is taken up in 400 ml of dimethylformamide and mixed with 88.5 ml (192.8 g 1.026 mol) of 1,2-dibromoethane. After 6 hours of stirring at 40 0 C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to pH 3-4 with 37% aqueous hydrochloric acid. 166 ml .(171 g 3.42 mol) of hydrazine hydrate is added to this reaction solution and heated under reflux for 30 hours. The reaction solution is set at pH 13 with solid potassium hydroxide. The reaction solution is subsequently concentrated by evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the solvent is removed again in a vacuum. The residue is mixed with 25 g of activated carbon and 150 ml of formaldehyde diethylacetal and heated under reflux for some time before the hot solution is filtered through a membrane. After the solution is cooled, the product is isolated by filtration. 35.9 g of cyclene (61% of theory) is obtained as a crystalline solid.
Example 9 1,4,7,10-Tetraazacyclododecane cyclene) g of triethylenetetramine (0.342 mol) is dissolved in 1 1 of ethanol and mixed at room temperature with 39 ml of glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which then is taken up in 400 ml of dimethylformamide and mixed with 81.2 ml (101.5 g 1.026 mol) of 1,2-dichloroethane. After 8 hours of stirring at 40 0 C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to pH 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g 3.42 mol) of hydrazine hydrate is added at room temperature to this reaction solution, and then it is heated under reflux for 30 hours. The reaction solution is set at pH 13 with solid potassium hydroxide. The reaction solution is subsequently concentrated by evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the solvent is removed again in a vacuum. The residue is mixed with g of activated carbon and 200 ml of toluene and heated under reflux for some time before the hot solution is filtered through a membrane. After the solution is cooled, the product is isolated by filtration. 35.8 g of cyclene (61% of theory) is obtained as a crystalline solid.
Example 1,4,7,10-Tetraazacyclododecane cyclene).
g of triethylenetetramine (0.342 mol) is dissolved in 1 1 of 2-propanol and mixed at room temperature with 39 ml of glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which then is taken up in 400 ml of dimethylformamide and mixed with 81.2 ml (101.5 g 1.026 mol) of 1,2-dichloroethane. After 8 hours of stirring at 40 0 C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to pH 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g 3.42 mol) of hydrazine hydrate is added to this reaction solution at room temperature and heated under reflux for 30 hours. The reaction solution is set at pH 13 with solid potassium hydroxide. The reaction solution is subsequently concentrated by evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the solvent is removed again in a vacuum. The residue is mixed with 25 g of activated carbon and 150 ml of formaldehyde diethylacetal and heated under reflux for some time before the hot solution is' filtered through a membrane. After the solution is cooled, the product is isolated by filtration. 37.2 g of cyclene (63% of theory) is obtained as a crystalline solid.
19a Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that the prior art forms part of the common general knowledge in Australia.
*00* *o *oooo o *o*
Claims (10)
1. Process for the production of cyclene H\ /H N N H H- H characterized in that in a single-pot process, triethylenetetramine is reacted with 40% glyoxal at 20 0 C to 80 0 C in a polar, protic solvent within 4 to 40 hours; after the solvent has been removed, the intermediate tricyclic compound that is thus formed is alkylated to the two secondary amine- nitrogens with a 1,2-difunctionalized alkylating agent X(CH 2 2 X, in which X stands for a nucleofuge group, in a polar aprotic solvent, optionally in the presence of an auxiliary base, at to 120 0 C within 2 to 24 hours; after the solvent has been removed, the thus obtained condensation product is treated with hydrazine hydrate in a polar protic solvent at a pH of 3 to 6 within 12 to 48 hours at reflux temperature; then the cyclene is released from the cyclene salt by adding a base, and after the reaction solution is evaporated to the dry state, it is isolated.
2. Process according to claim 1, wherein methanol, ethanol, isopropanol, butanol, glycol, water or mixtures thereof are used as polar protic solvents.
3. Process according to claim 1, wherein N,N- dimethylformamide (DMF), N,N-dimethylacetamide (DMAC), N- methylpyrrolidone (NMP), tetramethylurea, formamide or dimethylpropylene urea (DMPU) is used as a polar aprotic solvent.
4. Process according to claim 1, wherein 1, 2 -dibromoethane, 1,2-dichloroethane, 1,2-ditosylethane, 1,2-dimesylethane or 1,2- diiodoethane is used as an alkylating agent X(CH 2 2 X. Process according to claim 1, wherein sodium carbonate, potassium carbonate, calcium carbonate, sodium bicarbonate, potassium hydrogen carbonate, magnesium carbonate, magnesium hydrogen carbonate, lithium hydroxide or lithium carbonate is used as an auxiliary base that is optionally used in the condensation reaction with the 1,2-difunctionalized alkylating agent X(CH 2 2 X.
6. Process according to claim 1, wherein sodium hydroxide, potassium hydroxide, calcium hydroxide or a basic ion exchanger is used as a base to release cyclene.
7. Process according to-claim 1, wherein the reaction of oo :triethyleneeteramine is performed with glyoxal at 20 to 40 C ''within 15 to 20 hours.
8. Process according to claim 1, wherein the condensation reaction is performed with the 1,2-difunctionalized alkylating agent X(CH2) 2 X at 30 to 70 0 C and within 6 to 10 hours.
9. Process according to claim 1, wherein the reaction of the condensation product with hydrazine hydrate is performed within 25 to 35 hours.
10. Process according to claim 1, wherein the reaction *product is isolated by treating with toluene, trifluoro- methylbenzene or diethoxymethane the residue that is obtained after the reaction solution has been concentrated by evaporation.
11. Process for the production of cyclene substantially as hereinbefore described with reference to the examples. DATED THIS 12th day of May, 2003. SCHERING AKTIENGESELLSCHAFT By Its Patent Attorneys DAVIES COLLISON CAVE oO *oo 'o oooo ooo o*oo
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19856481A DE19856481C1 (en) | 1998-12-02 | 1998-12-02 | Process for the production of cycles |
DE19856481 | 1998-12-02 | ||
PCT/EP1999/009089 WO2000032581A1 (en) | 1998-12-02 | 1999-11-17 | Method of producing cyclene |
Publications (2)
Publication Number | Publication Date |
---|---|
AU1654300A AU1654300A (en) | 2000-06-19 |
AU764260B2 true AU764260B2 (en) | 2003-08-14 |
Family
ID=7890308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU16543/00A Ceased AU764260B2 (en) | 1998-12-02 | 1999-11-17 | Method of producing cyclene |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1135376B1 (en) |
JP (1) | JP4636690B2 (en) |
KR (1) | KR100639270B1 (en) |
CN (1) | CN1155583C (en) |
AT (1) | ATE250042T1 (en) |
AU (1) | AU764260B2 (en) |
CA (1) | CA2353680C (en) |
CZ (1) | CZ300157B6 (en) |
DE (2) | DE19856481C1 (en) |
DK (1) | DK1135376T3 (en) |
ES (1) | ES2209530T3 (en) |
HK (1) | HK1044148B (en) |
IL (1) | IL143079A (en) |
NO (1) | NO318054B1 (en) |
NZ (1) | NZ512051A (en) |
PT (1) | PT1135376E (en) |
SK (1) | SK285372B6 (en) |
WO (1) | WO2000032581A1 (en) |
ZA (1) | ZA200105406B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2830253B1 (en) | 2001-09-28 | 2005-02-04 | Air Liquide | NOVEL PROCESS FOR THE PREPARATION OF C-FUNCTIONALIZED NITROGEN MACROCYCLES AND NOVEL INTERMEDIATES OBTAINED |
CN103360333B (en) * | 2013-07-22 | 2016-03-30 | 厦门市华兴化工有限公司 | A kind of preparation method of high purity methyl-isochondodendrine |
CN106490298B (en) * | 2016-11-28 | 2020-05-22 | 华南理工大学 | High-dispersity plant protein and preparation method thereof |
US10344115B2 (en) | 2017-05-25 | 2019-07-09 | International Business Machines Corporation | Amine glyoxal resins |
KR20190108383A (en) | 2018-03-14 | 2019-09-24 | 주식회사 지에이치바이오텍 | Novel synthesis of cyclen using oxamide and lithium aluminium hydride |
EP4067348A1 (en) | 2021-03-30 | 2022-10-05 | Bracco Imaging SPA | Process for the preparation of cyclen |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9504922D0 (en) * | 1995-03-10 | 1995-04-26 | Nycomed As | Process |
IT1284046B1 (en) * | 1996-06-21 | 1998-05-08 | Bracco Spa | PROCESS FOR THE PREPARATION OF TETRAAZAMACROCYCLES |
IT1290457B1 (en) * | 1997-04-04 | 1998-12-03 | Bracco Spa | PROCESS FOR THE PREPARATION OF TETRAAZAMACROCYCLES |
IT1291673B1 (en) * | 1997-04-28 | 1999-01-19 | Bracco Spa | PROCESS FOR THE PREPARATION OF 1,4,7,10 - TETRAAZACICLODODECANO |
-
1998
- 1998-12-02 DE DE19856481A patent/DE19856481C1/en not_active Expired - Lifetime
-
1999
- 1999-11-17 CA CA002353680A patent/CA2353680C/en not_active Expired - Fee Related
- 1999-11-17 IL IL14307999A patent/IL143079A/en not_active IP Right Cessation
- 1999-11-17 AT AT99959326T patent/ATE250042T1/en active
- 1999-11-17 JP JP2000585223A patent/JP4636690B2/en not_active Expired - Fee Related
- 1999-11-17 SK SK724-2001A patent/SK285372B6/en not_active IP Right Cessation
- 1999-11-17 CN CNB998140635A patent/CN1155583C/en not_active Expired - Fee Related
- 1999-11-17 NZ NZ512051A patent/NZ512051A/en not_active IP Right Cessation
- 1999-11-17 WO PCT/EP1999/009089 patent/WO2000032581A1/en active IP Right Grant
- 1999-11-17 PT PT99959326T patent/PT1135376E/en unknown
- 1999-11-17 CZ CZ20011915A patent/CZ300157B6/en not_active IP Right Cessation
- 1999-11-17 DE DE59907056T patent/DE59907056D1/en not_active Expired - Lifetime
- 1999-11-17 AU AU16543/00A patent/AU764260B2/en not_active Ceased
- 1999-11-17 DK DK99959326T patent/DK1135376T3/en active
- 1999-11-17 EP EP99959326A patent/EP1135376B1/en not_active Expired - Lifetime
- 1999-11-17 ES ES99959326T patent/ES2209530T3/en not_active Expired - Lifetime
- 1999-11-17 KR KR1020017006832A patent/KR100639270B1/en not_active IP Right Cessation
-
2001
- 2001-06-01 NO NO20012703A patent/NO318054B1/en not_active IP Right Cessation
- 2001-06-29 ZA ZA200105406A patent/ZA200105406B/en unknown
-
2002
- 2002-06-28 HK HK02104835.9A patent/HK1044148B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NZ512051A (en) | 2003-10-31 |
JP4636690B2 (en) | 2011-02-23 |
EP1135376B1 (en) | 2003-09-17 |
HK1044148B (en) | 2005-04-01 |
CN1155583C (en) | 2004-06-30 |
ES2209530T3 (en) | 2004-06-16 |
PT1135376E (en) | 2004-02-27 |
KR20010080648A (en) | 2001-08-22 |
SK7242001A3 (en) | 2001-12-03 |
EP1135376A1 (en) | 2001-09-26 |
ATE250042T1 (en) | 2003-10-15 |
SK285372B6 (en) | 2006-12-07 |
KR100639270B1 (en) | 2006-10-27 |
HK1044148A1 (en) | 2002-10-11 |
DK1135376T3 (en) | 2004-01-19 |
NO20012703D0 (en) | 2001-06-01 |
DE59907056D1 (en) | 2003-10-23 |
ZA200105406B (en) | 2002-07-25 |
IL143079A (en) | 2005-08-31 |
NO318054B1 (en) | 2005-01-24 |
CA2353680C (en) | 2008-09-09 |
AU1654300A (en) | 2000-06-19 |
WO2000032581A1 (en) | 2000-06-08 |
CA2353680A1 (en) | 2000-06-08 |
CZ20011915A3 (en) | 2001-09-12 |
JP2003522114A (en) | 2003-07-22 |
NO20012703L (en) | 2001-06-01 |
IL143079A0 (en) | 2002-04-21 |
CN1329603A (en) | 2002-01-02 |
DE19856481C1 (en) | 2000-07-06 |
CZ300157B6 (en) | 2009-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL105807A (en) | Processes for the preparation of tetraayacyclododecane and tetraazacyclo-tetradecane derivatives | |
JP2009185077A (en) | Method for producing 1,4,7,10-tetraazacyclododecane | |
AU764260B2 (en) | Method of producing cyclene | |
CZ20031641A3 (en) | Lithium complexes of N-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, process of their preparation and use | |
CN115260167A (en) | 3-tetrazolylmethyl-1, 3, 5-triazine-2, 4-diketone compound and preparation method and application thereof | |
US6156890A (en) | Process for the production of cyclene | |
JP2008531642A (en) | Method for obtaining pharmaceutically active compound irbesartan and synthetic intermediates thereof | |
US20050038297A1 (en) | Synthesis and purification of 1,3,5-triamino-2,4,6-trinitrobenzene (TATB) | |
US7732631B2 (en) | Eco-friendly process for the preparation of 2-Chlorobenzylidene-Malononitrile (CS) | |
JP2006527241A (en) | Cis-8B-methyldecahydro-2A, 4A, 6A, 8A-tetraazacyclopenta [FG] acenaphthylene, cis-decahydro-2A, 4A, 6A, 8A-tetraazacyclopenta [FG] acenaphthylene, cyclen and functionalization Cyclen | |
KR100614535B1 (en) | A Process for the Preparation of 1,4,7,10-Tetraazacyclododecane | |
KR100809159B1 (en) | Improved method for preparing losartan | |
AU684672B2 (en) | New method for the preparation of 3,4-dihydroxy-5-nitrobenzaldehyde | |
NO313139B1 (en) | Process for the preparation of 1,4,7,10-tetraazacyclododecane | |
US5625066A (en) | Optically active hydroquinine (amino-3 phenyl)-1 ethanesulfonate, preparation and use thereof | |
JPH05339236A (en) | Production of 2,3-diaminopyridines | |
GB2170806A (en) | N-(b-mercapto-iso-butyryl)proline, derivatives and a process for their preparation | |
Suwiński et al. | Synthesis of 2‐methyl‐4 (5)‐nitro [15N1 (3)] imidazole from 2‐methyl‐4 (5)‐nitroimidazole | |
JP2004067544A (en) | Method for producing highly pure bis-(1(2)h-tetrazol-5-yl)amine | |
US3915985A (en) | Process for preparing naphth{8 1,2-d{9 imidazole and intermediate therefor 1-hydroxynaphth{8 1,2-d{9 imidazole hydrate | |
JPS61172846A (en) | Method of optical resolution of (+-)-2-chloroprorionic acid | |
JPS6270344A (en) | Production of nitrophenoxyamine | |
JPH07101915A (en) | Production of 4,4',4"-triamino-2,5-dimethoxytriphenylamine | |
PL175287B1 (en) | Method of obtaining 1,2,3,4,10,14b-hexahydro-2-methylodibenzo(c,f)-pyrasino-(1,2-a)-azepin | |
WO2010069397A1 (en) | Process for the preparation of diclofenac epolamine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |